Hikma has succeeded in convincing a US district court to dismiss allegations that it induced infringement of patents protecting a cardiovascular indication for Amarin’s Vascepa (icosapent ethyl) with its skinny-label generic.
Following Hikma’s launch of the first US generic version of Vascepa in November 2020 – in the wake of success in separate patent litigation (Also see "Hikma Launches US Vascepa Rival As Amarin Appeal Denied" - Generics Bulletin, 5 November, 2020.) – Amarin sued the firm again, this time accusing it of inducing infringement of three Vascepa patents
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?